Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.67 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11245638 | 0.87 | LMNA (0.67) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL17897657 | 0.86 | LMNA (0.62) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11601229 | 0.85 | ASAH1 (0.80) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL17278298 | 0.83 | LMNA (0.69) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL10459087 | 0.83 | ASAH1 (0.72) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11665245 | 0.82 | LMNA (0.61) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL10458638 | 0.82 | ASAH1 (0.90) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11251920 | 0.82 | LMNA (0.68) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL9664618 | 0.82 | LMNA (0.67) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL17897713 | 0.81 | LMNA (0.67) | LMNACYP3A4CYP2D6MAPK3ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | WEIFANG BOCHUANG INTERNATIONAL ACADEMY OF BIOTECHNOLOGY AND MEDICINE (CN) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | ANPEP, DNPEP, ENPEP | LMNA 1905/4885CYP3A4 1177/4885CYP2D6 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.